Dogwood Therapeutics posts new investor presentation

Dogwood Therapeutics, Inc. filed a current report to let the market know it has posted an investor presentation on its website.

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. filed a current report to let the market know it has posted an investor presentation on its website. The presentation, dated October 9, 2025, may be used in discussions with investors, analysts, collaborators, vendors and other third parties.

The presentation is furnished as Exhibit 99.1 to the report and is provided under a disclosure category that is not treated as formally filed with the SEC. This means it is available for information purposes but is not automatically incorporated into Dogwood’s Securities Act filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dogwood Therapeutics (DWTX) report in this 8-K filing?

Dogwood Therapeutics reported that it posted an updated investor presentation to its website on October 9, 2025. The same presentation is furnished to the SEC as Exhibit 99.1 to help inform external stakeholders about the company.

What is Exhibit 99.1 in Dogwood Therapeutics’ (DWTX) latest 8-K?

Exhibit 99.1 is a presentation dated October 9, 2025 that Dogwood Therapeutics may use with investors, analysts, collaborators, vendors, and other third parties. It is attached to the 8-K for convenience and transparency.

Is the Dogwood Therapeutics (DWTX) investor presentation considered filed with the SEC?

No. The investor presentation attached as Exhibit 99.1 is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act. It is also not automatically incorporated by reference into Securities Act filings.

Why did Dogwood Therapeutics (DWTX) furnish its presentation on Form 8-K?

Dogwood Therapeutics furnished the presentation so investors and other stakeholders can access the same information made available in meetings. Using Form 8-K ensures broad, equal access to the materials through the SEC’s public system.

Who signed the Dogwood Therapeutics (DWTX) 8-K related to the presentation?

The 8-K was signed on behalf of Dogwood Therapeutics by Angela Walsh, who serves as Chief Financial Officer, Corporate Secretary and Treasurer. Her signature confirms the company’s authorization of the furnished disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/09/2025 - 04:15 PM Learn about SEC filing dates

0001818844false00018188442025-10-092025-10-09

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported):  October 9, 2025

​

DOGWOOD THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

​

​	​	​
Delaware	001-39811	85-4314201
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

​ ​	​
44 Milton Avenue Alpharetta, GA	30009
(Address of principal executive offices)	(Zip Code)

​

Registrant’s telephone number, including area code:  (866) 620-8655

​

(Former name or former address, if changed since last report): N/A

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	DWTX	Nasdaq Capital Market

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company       ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐

​

​

​

​

Item 7.01 Regulation FD Disclosure.

On October 9, 2025, the Company posted a presentation to its website that may be used by the Company from time to time with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is furnished as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.

​

​

Item 9.01 Financial Statements and Exhibits.

​

(d)Exhibits.

​

​	​	​
Exhibit Number		Description
99.1	​	Presentation, dated October 9, 2025 (furnished herewith).
104	​	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

​

​

​

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
	DOGWOOD THERAPEUTICS, INC.
	By:	/s/ Angela Walsh
	Name:	Angela Walsh
​	Title:	Chief Financial Officer, Corporate Secretary and Treasurer
October 9, 2025	​	​

​

​

​

3